Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

FORM	2017 Л Л							OMB A	PPROVAL	
	UNITED	STATES		COMMISSION	OMB Number:	3235-0287				
Check t	aar									
subject Section	to SIAIE N 16.	MENT O	OF CHANGES IN BENEFICIAL (SECURITIES				WNERSHIP OF	Expires: Estimated a burden hou	•	
Form 4 Form 5 obligation may con <i>See</i> Inst 1(b).	Filed pur ons ttinue. Section 17((a) of the l	Public U	tility Hol	lding Cor		nge Act of 1934, of 1935 or Sectio 940	response n	0.5	
Print or Type	Responses)									
1. Name and COHEN C	2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer					
<i>(</i> 7)	(First) (A	Middle)				nc. [XENE	[] (Chec	k all applicable	e)	
(Last) C/O XENC PHARMA	3. Date of Earliest Transaction (Month/Day/Year) 03/13/2017			Director 10% Owner Officer (give title Other (specify below) below) VP, Biology						
3650 GILN	IORE WAY									
				4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	SecuritiesFBeneficially(Owned(5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities bene	ficially own	ned directly	or indirectly.			
					Perso inforn requir	ns who rest nation cont ed to resp ys a curre	spond to the collec tained in this form ond unless the forn ntly valid OMB con	are not m	EC 1474 (9-02)	
	Tab	le II - Deriv	vative Sec	curities Acc	uired, Dis	posed of, or	Beneficially Owned			

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Γ

Underlying Securities

Expiration Date

Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

Security (Instr. 3)			any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)					
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 8.4	03/13/2017		А	20,000	<u>(1)</u>	03/12/2027	Common Shares	20,000				
Reporting Owners													
Reporting Owner Name / Address			Rela	tionships									
			Director	10% Owner	Officer	Other							
COHEN CHARLES J. C/O XENON PHARMACEUTICALS INC 200 - 3650 GILMORE WAY BURNABY, A1 V5G 4W8			INC		VP, Biolo								
Signa	tures												
	/s/ Joanne Smartt, Attorney-in-fact 03												
**Signature of Reporting Person			Date										

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (